The short treatment with the angiotensin receptor blocker candesartan surveyed by telemedicine (STAR CAST) study: Rationale and study design

Hypertension Research

Volumn 31, Issue 10, 2008, Pages 1843-1849

  Sasamura, Hiroyuki ^a   Nakaya, Hideaki ^a,b   Julius, Stevo ^a   Takebayashi, Toru ^b,c   Sato, Yuji ^b   Uno, Hajime ^d   Takeuchi, Masahiro ^d   Ishiguro, Kimiko ^a   Murakami, Marohito ^e   Ryuzaki, Munekazu ^f   Itoh, Hiroshi ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c KEIO UNIVERSITY   (Japan)

^d KITASATO UNIVERSITY   (Japan)

^e Hino Municipal Hospital   (Japan)

^f KAWASAKI MUNICIPAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANDESARTAN HEXETIL; NIFEDIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; CANDESARTAN; TETRAZOLE DERIVATIVE;

ADULT; ARTICLE; BLOOD PRESSURE FLUCTUATION; BLOOD PRESSURE MONITORING; BORDERLINE HYPERTENSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG WITHDRAWAL SUCCESS RATE; FAMILY HISTORY; HOME MONITORING; HUMAN; JAPAN; MULTICENTER STUDY; PHARMACOLOGICAL PARAMETERS; PREHYPERTENSION; RANDOMIZED CONTROLLED TRIAL; REMISSION; SHORT COURSE THERAPY; SLOW RELEASE FORMULATION; TELEMONITORING; HYPERTENSION; METHODOLOGY; TELEMEDICINE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TELEMEDICINE; TETRAZOLES;

EID: 58149385851     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.1843     Document Type: Article

References (21)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J: Global burden of hypertension: Analysis of world-wide data. Lancet 2005; 365: 217-223.
2. Alderman M, Ogihara T: Global challenge for overcoming high blood pressure: Fukuoka statement, 19 October 2006. J Hypertens 2007; 25: 727.
3. Japanese Society of Hypertension: Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). Hypertens Res 2006; 29 (Suppl): S1-S105.
4. Chobanian AV, Bakris GL, Black HR, et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003; 289: 2560-2572.
5. Cifkova R, Erdine S, Fagard R, et al: Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens 2003; 21: 1779-1786.
6. Whitworth JA: 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983-1992.
7. Harrap SB, Van der Merwe WK, Griffin SA, Macpherson F, Lever AF: Brief angiotensin converting enzyme inhibitor treatment in young spontaneously hypertensive rats reduces blood pressure long-term. Hypertension 1990; 16: 603-614.
8. Wu JN, Berecek KH: Prevention of genetic hypertension by early treatment of spontaneously hypertensive rats with the angiotensin converting enzyme inhibitor captopril. Hypertension 1993; 22: 139-146.
9. Morton JJ, Beattie EC, MacPherson F: Angiotensin II receptor antagonist losartan has persistent effects on blood pressure in the young spontaneously hypertensive rat: Lack of relation to vascular structure. J Vasc Res 1992; 29: 264-269.
10. Nakaya H; Sasamura H, Hayashi M, Saruta T: Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis. J Am Soc Nephrol 2001; 12: 659-666.
11. Nakaya H, Sasamura H, Mifune M, et al: Prepubertal treatment with angiotensin receptor blocker causes partial attenuation of hypertension and renal damage in adult Dahl salt-sensitive rats. Nephron 2002; 91: 710-718.
12. Ishiguro K, Sasamura H, Sakamaki Y, Itoh H, Saruta T: Developmental activity of the renin-angiotensin system during the "critical period" modulates later L-NAME-induced hypertension and renal injury. Hypertens Res 2007; 30: 63-75.
13. Julius S, Nesbitt SD, Egan BM, et al: Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354: 1685-1697.
14. Ishiguro k, Sasamura H, Sakamaki Y, Hayashi K, Saruta T, Itoh H: Use of transient 'pulse' therapy with antihypertensive agents to induce regression of established hypertension in spotaneously hypertensive rats. J Am Soc Nephrol 2007; 18: 157A.
15. Sakamaki Y, Sasamura H, Ikeda S, Ikegami N, Saruta T: Comparison of health costs associated with treatment of hypertension with a calcium channel blocker and angiotensin-converting enzyme inhibitor in the United States and Japan. Hypertens Res 2006; 29: 333-338.
16. Ryuzaki M, Nakamoto H, Nishida E, et al: Crossover study of amlodipine versus nifedipine CR with home blood pressure monitoring via cellular phone: Internet-mediated open-label crossover trial of calcium channel blockers for hypertension (i-TECHO trial): J Hypertens 2007; 25: 2352-2358.
17. Course of blood pressure in mild hypertensives after withdrawal of long term antihypertensive treatment. Medical Research Council Working Party on Mild Hypertension. Br Med J (Clin Res Ed) 1986; 293: 988-992.
18. Langford HG, Blaufox MD, Oberman A, et al: Dietary therapy slows the return of hypertension after stopping prolonged medication. JAMA 1985; 253: 657-664.
19. Maland LJ, Lutz LJ, Castle CH: Effects of withdrawing diuretic therapy on blood pressure in mild hypertension. Hypertension 1983; 5 539-544.
20. Return of elevated blood pressure after withdrawal of antihypertensive drugs. Circulation 1975; 51: 1107-1113.
21. Skov K, Eiskjaer H, Hansen HE, Madsen JK, Kvist S, Mulvany MJ: Treatment of young subjects at high familial risk of future hypertension with an angiotensin-receptor blocker. Hypertension 2007; 50: 89-95.